PURPOSE: Ectopic expression of GRM1 in murine melanocytes results in transformation into a form of melanoma, and more than 60% of human melanoma samples tested ectopically express GRM1. Stimulation of this receptor in vitro results in up-regulation of activated extracellular signal-regulated kinase (ERK). Furthermore, a xenograft model of melanoma treated with riluzole, an oral GRM1 blocking agent, showed decreased tumor growth compared with the untreated controls. We have now completed a phase 0 trial of riluzole in patients with melanoma. EXPERIMENTAL DESIGN: Patients enrolled on this trial underwent a pretreatment biopsy, took 200 mg of oral riluzole per day for 14 days, and then underwent resection of their remaining tumor. We compared the levels of pERK and pAKT in the pretreatment and post-treatment samples and assessed the metabolic activity of pretreatment and post-treatment tumors using fluorodeoxyglucose positron emission tomography (FDG-PET) scanning. RESULTS: We accrued 12 patients and all expressed GRM1. We found a significant decrease in pAKT and/or pERK in post-treatment tumor samples as compared with pretreatment samples in 4 (34%) patients. These four patients had a significant decrease in FDG-PET intensity post-treatment as well. Two other patients had a clinical response with no corresponding metabolic response; five patients had similar pretreatment and post-treatment FDG-PET scan findings; and one patient had progressive disease. CONCLUSIONS: Our data show that glutamate blockade with riluzole can inhibit signaling through the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT pathways and suppress the metabolic activity of melanoma. The ectopic expression of metabotropic glutamate receptors may be important in the pathogenesis of human melanoma, and targeting this pathway may be an effective therapy.
PURPOSE: Ectopic expression of GRM1 in murine melanocytes results in transformation into a form of melanoma, and more than 60% of humanmelanoma samples tested ectopically express GRM1. Stimulation of this receptor in vitro results in up-regulation of activated extracellular signal-regulated kinase (ERK). Furthermore, a xenograft model of melanoma treated with riluzole, an oral GRM1 blocking agent, showed decreased tumor growth compared with the untreated controls. We have now completed a phase 0 trial of riluzole in patients with melanoma. EXPERIMENTAL DESIGN:Patients enrolled on this trial underwent a pretreatment biopsy, took 200 mg of oral riluzole per day for 14 days, and then underwent resection of their remaining tumor. We compared the levels of pERK and pAKT in the pretreatment and post-treatment samples and assessed the metabolic activity of pretreatment and post-treatment tumors using fluorodeoxyglucose positron emission tomography (FDG-PET) scanning. RESULTS: We accrued 12 patients and all expressed GRM1. We found a significant decrease in pAKT and/or pERK in post-treatment tumor samples as compared with pretreatment samples in 4 (34%) patients. These four patients had a significant decrease in FDG-PET intensity post-treatment as well. Two other patients had a clinical response with no corresponding metabolic response; five patients had similar pretreatment and post-treatment FDG-PET scan findings; and one patient had progressive disease. CONCLUSIONS: Our data show that glutamate blockade with riluzole can inhibit signaling through the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/AKT pathways and suppress the metabolic activity of melanoma. The ectopic expression of metabotropic glutamate receptors may be important in the pathogenesis of humanmelanoma, and targeting this pathway may be an effective therapy.
Authors: O Ben-Izhak; M Bar-Chana; L Sussman; V Dobiner; J Sandbank; M Cagnano; H Cohen; E Sabo Journal: Histopathology Date: 2002-12 Impact factor: 5.087
Authors: Pamela M Pollock; Karine Cohen-Solal; Raman Sood; Jin Namkoong; Jeffrey J Martino; Aruna Koganti; Hua Zhu; Christiane Robbins; Izabela Makalowska; Seung-Shick Shin; Yari Marin; Kathleen G Roberts; Laura M Yudt; Amy Chen; Jun Cheng; Arturo Incao; Heather W Pinkett; Christopher L Graham; Karen Dunn; Steven M Crespo-Carbone; Kerine R Mackason; Kevin B Ryan; Daniel Sinsimer; James Goydos; Kenneth R Reuhl; Michael Eckhaus; Paul S Meltzer; William J Pavan; Jeffrey M Trent; Suzie Chen Journal: Nat Genet Date: 2003-05 Impact factor: 38.330
Authors: D S Tyler; M Onaitis; A Kherani; A Hata; E Nicholson; M Keogan; S Fisher; E Coleman; H F Seigler Journal: Cancer Date: 2000-09-01 Impact factor: 6.860
Authors: J E Mortimer; F Dehdashti; B A Siegel; K Trinkaus; J A Katzenellenbogen; M J Welch Journal: J Clin Oncol Date: 2001-06-01 Impact factor: 44.544
Authors: G J Groeneveld; H J M Van Kan; S Kalmijn; J H Veldink; H-J Guchelaar; J H J Wokke; L H Van den Berg Journal: Neurology Date: 2003-10-28 Impact factor: 9.910
Authors: Brian A Wall; Lumeng J Yu; Atif Khan; Bruce Haffty; James S Goydos; Suzie Chen Journal: Pigment Cell Melanoma Res Date: 2014-11-28 Impact factor: 4.693
Authors: Maithao N Le; Joseph L-K Chan; Stephen A Rosenberg; Adam S Nabatian; Kim T Merrigan; Karine A Cohen-Solal; James S Goydos Journal: J Invest Dermatol Date: 2010-05-27 Impact factor: 8.551
Authors: Travis L Biechele; Nathan D Camp; Daniel M Fass; Rima M Kulikauskas; Nick C Robin; Bryan D White; Corinne M Taraska; Erin C Moore; Jeanot Muster; Rakesh Karmacharya; Stephen J Haggarty; Andy J Chien; Randall T Moon Journal: Chem Biol Date: 2010-11-24
Authors: Jeffrey C Pelletier; Suzie Chen; Haiyan Bian; Raj Shah; Garry R Smith; Jay E Wrobel; Allen B Reitz Journal: ACS Med Chem Lett Date: 2018-06-15 Impact factor: 4.345
Authors: D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker Journal: Cancer Causes Control Date: 2012-10-23 Impact factor: 2.506